• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ascentage Pharma (SEHK:6855) Stock Faces Rising Losses Despite Revenue Growth

    Simply Wall St·08/21/2026 10:36:21
    語音播報

    Ascentage Pharma Group International came into this print on the back of a weak tape, with the stock down about 21% over three months and closing at HK$32.86 on Friday. The market has been treating the company as a high risk, high expectation biotech story. Today's H1 2026 earnings underline why, with total revenue of ¥302.2m set against a net loss of ¥816.7m and a price to sales multiple of 16.1x that still runs ahead of Hong Kong biotech peers.

    Impressed by the revenue traction at Ascentage Pharma Group International but uneasy about the scale of losses and rich P/S multiple? Take a look at our list of solid balance sheet and fundamentals stocks (424 results).

    H1 2026 Earnings Summary

    • Revenue (H1 2026 vs H1 2025): ¥302.2m vs. ¥233.7m (up about 29%)
    • Net Loss (H1 2026 vs H1 2025): ¥816.7m loss vs. ¥590.8m loss (loss widened about 38%)
    • Basic EPS (H1 2026 vs H1 2025): ¥2.19 loss per share vs. ¥1.73 loss per share (loss per share widened about 27%)
    • Trailing 12-Month Revenue vs. Net Loss (to H1 2026 vs to H1 2025): ¥642.6m revenue and ¥1.47b net loss vs. ¥574.1m revenue and ¥1.24b net loss (higher revenue alongside a larger trailing loss)

    If you prefer clean charts instead of dense financial tables and lengthy earnings summaries, you can see Ascentage Pharma Group International's full financial picture, including a clear view of its net losses alongside revenue trends, in our company report for Ascentage Pharma Group International.

    SEHK:6855 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    SEHK:6855 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Ascentage Pharma’s Bull Story Meets Concrete Milestones

    The bullish pitch on Ascentage Pharma Group International is that this is no longer just a clinical story but a company building a real commercial base while pushing a broad late stage pipeline toward global markets. The H1 2026 numbers and commentary show clear evidence of that shift. Product sales of ¥302.2m revenue on the period’s figures are now the bulk of revenue, and management confirms two approved products in China with a growing field force targeting roughly 2,000 hospitals.

    The narrative of a deep late stage engine is also backed by facts. There are nine registrational trials running, with four cleared by both the US Food and Drug Administration and the European Medicines Agency. Clinical data presented at ASCO 2026 and EHA 2026 for olverembatinib, lisaftoclax and alrizomadlin supports continued investment in these programs and aligns with the goal of becoming a global hematology oncology company.

    Compare that commercial progress and late stage pipeline at Ascentage Pharma Group International with how institutional analysts are calibrating upside and risk on SEHK:6855. See the consensus price target analysis for Ascentage Pharma Group International to understand where the Street stands after these H1 2026 results.

    Ascentage Pharma Bear Case: Cash Quality Questions Linger

    The core bearish claim on Ascentage Pharma Group International is that revenue is flattered by one off Takeda and other partnership cash, while the underlying business is still an early stage loss maker with funding risk. The latest H1 2026 numbers partially blunt this. Product sales of ¥302.2m are now the bulk of reported revenue, so near term top line is less dependent on fresh partner options. However, the net loss widened to ¥816.7m and the trailing 12 month loss reached ¥1.47b, which means the commercial base is still far from covering the cost of the pipeline and global build out.

    Bears also focus on funding and dilution risk. Management highlights a US$279.4m cash balance and a stated runway to end 2027. That defers the funding question but does not remove it if pivotal trials or reimbursement milestones slip.

    After losses of this scale, are funding risks and execution setbacks just starting to surface, or are they far deeper? Review our risk analysis for Ascentage Pharma Group International which shows 1 important warning sign

    Stay Ahead With Simply Wall St

    If the mix of growing product revenue and sizeable losses at Ascentage Pharma Group International has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the story develops. Once you own shares, keep your decisions clean and focused with the Portfolio Command Center that highlights the most important events for your holdings. For a longer term view, use the Community to see how other investors are thinking about risks, milestones and potential catalysts. By surfacing hidden strengths and problems early, Simply Wall St helps you stay ahead of the market instead of reacting after the fact.

    Seeking Alternatives Beyond Ascentage Pharma?

    Fresh ideas often move first when momentum builds, and the best entry points can be gone once the crowd catches on. Scan under the radar for now and act promptly.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.